Friday, September 16, 2016

Allegra


Allegra is a brand name of fexofenadine, approved by the FDA in the following formulation(s):


ALLEGRA (fexofenadine hydrochloride - suspension; oral)



  • Manufacturer: SANOFI AVENTIS US

    Approval date: October 16, 2006

    Strength(s): 30MG/5ML [RLD]

Has a generic version of Allegra been approved?


No. There is currently no therapeutically equivalent version of Allegra available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Allegra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Piperidine derivatives
    Patent 5,578,610
    Issued: November 26, 1996
    Inventor(s): D'Ambra; Thomas E.
    Assignee(s): Albany Molecular Research, Inc.
    The present invention relates to substantially pure piperidine derivative compounds of the formulae: ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; R.sub.3 is --COOH or --COOR.sub.4 ; R.sub.4 has 1 to 6 carbon atoms; A, B, and D are the substituents of their respective rings each of which may be different or the same and are hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents. A process of preparing such piperidine derivative compounds in substantially pure form is also disclosed.
    Patent expiration dates:

    • November 26, 2013
      ✓ 
      Patent use: USE IN TREATING ALLERGIC REACTIONS


    • November 26, 2013
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • May 26, 2014
      ✓ 
      Patent use: USE IN TREATING ALLERGIC REACTIONS
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 5,738,872
    Issued: April 14, 1998
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marquerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical compositions for piperidinalkanol compounds
    Patent 5,855,912
    Issued: January 5, 1999
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 5,932,247
    Issued: August 3, 1999
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Method of providing an antihistaminic effect in a hepatically impaired patient
    Patent 6,037,353
    Issued: March 14, 2000
    Inventor(s): Woodward; James K. & Okerholm; Richard A. & Eller; Mark G. & McNutt; Bruce E.
    Assignee(s): Hoechst Marion Roussel, Inc.
    The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Patent expiration dates:

    • March 14, 2017
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS


    • March 14, 2017
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS


    • September 14, 2017
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS
      ✓ 
      Pediatric exclusivity




  • Pharmaceutical composition for piperidinoalkanol compounds
    Patent 6,113,942
    Issued: September 5, 2000
    Inventor(s): Ortyl; Thomas T. & Skultety; Paul F. & Mitchell; Kristen C. & Phadke; Deepak S. & Attarchi; Faraneh & Pierce; Marguerite L. & Schoeneman; Aaron W. & Schnitz; Joseph M.
    Assignee(s): Aventis Pharmaceuticals Inc.
    The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient.
    Patent expiration dates:

    • February 28, 2015


    • August 28, 2015
      ✓ 
      Pediatric exclusivity




  • Method of providing an antihistaminic effect in a hepatically impaired patient
    Patent 6,187,791
    Issued: February 13, 2001
    Inventor(s): Woodward; James K. & Okerholm; Richard A. & Eller; Mark G. & McNutt; Bruce E.
    Assignee(s): Merrell Pharmaceuticals Inc.
    The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Patent expiration dates:

    • May 11, 2012
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS


    • May 11, 2012
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS


    • November 11, 2012
      ✓ 
      Patent use: TREATMENT OF ALLERGIC RHINITIS
      ✓ 
      Pediatric exclusivity




  • Method of providing an antihistaminic effect in a hepatically impaired patient
    Patent 6,399,632
    Issued: June 4, 2002
    Inventor(s): James K.; Woodward & Richard A.; Okerholm & Mark G.; Eller & Bruce E.; McNutt
    Assignee(s): Merrell Pharmaceuticals Inc.
    The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula wherein R1 is hydrogen or hydroxy; R2 is hydrogen; or R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; R3 is —COOH or —COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
    Patent expiration dates:

    • May 11, 2012
      ✓ 
      Patent use: METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS


    • May 11, 2012
      ✓ 
      Patent use: RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS


    • November 11, 2012
      ✓ 
      Patent use: METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
      ✓ 
      Pediatric exclusivity




  • Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
    Patent 7,135,571
    Issued: November 14, 2006
    Inventor(s): Henton; Daniel R & McCarty; Frederick J & Tripp; Susan I & DeWitt; Jill E
    Assignee(s): Aventis Pharmaceuticals, Inc.
    The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
    Patent expiration dates:

    • May 18, 2014
      ✓ 
      Drug substance


    • November 18, 2014
      ✓ 
      Pediatric exclusivity




  • Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
    Patent 7,138,524
    Issued: November 21, 2006
    Inventor(s): McCarty; Frederick J. & Carr; Albert A.
    Assignee(s): Aventis Pharmaceuticals, Inc.
    The present invention is related to novel processes for preparing anhydrous and hydrated forms of piperidine derivatives, polymorphs and pseudomorphs thereof of the formulas which are useful as antihistamines, antiallergic agents and bronchodilators.
    Patent expiration dates:

    • May 18, 2014
      ✓ 
      Drug substance


    • November 18, 2014
      ✓ 
      Pediatric exclusivity



See also...

  • Allegra Consumer Information (Drugs.com)
  • Allegra Consumer Information (Wolters Kluwer)
  • Allegra Suspension Consumer Information (Wolters Kluwer)
  • Allegra Consumer Information (Cerner Multum)
  • Allegra Advanced Consumer Information (Micromedex)
  • Allegra AHFS DI Monographs (ASHP)
  • Fexofenadine Consumer Information (Wolters Kluwer)
  • Fexofenadine Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Fexofenadine Suspension Consumer Information (Wolters Kluwer)
  • Fexofenadine Consumer Information (Cerner Multum)
  • Fexofenadine Advanced Consumer Information (Micromedex)
  • Fexofenadine Hydrochloride AHFS DI Monographs (ASHP)

No comments:

Post a Comment